Arcutis Biotherapeutics, Inc.
ARQT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $99 | $82 | $66 | $71 |
| % Growth | 21.7% | 23.8% | -7.7% | – |
| Cost of Goods Sold | $9 | $7 | $9 | $7 |
| Gross Profit | $91 | $74 | $57 | $64 |
| % Margin | 91.2% | 90.8% | 86.6% | 90.3% |
| R&D Expenses | $20 | $19 | $18 | $14 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $62 | $69 | $64 | $58 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $82 | $89 | $82 | $72 |
| Operating Income | $9 | -$15 | -$25 | -$8 |
| % Margin | 8.6% | -17.9% | -37.3% | -10.7% |
| Other Income/Exp. Net | -$1 | -$1 | -$0 | -$3 |
| Pre-Tax Income | $7 | -$16 | -$25 | -$10 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $7 | -$16 | -$25 | -$11 |
| % Margin | 7.5% | -19.5% | -38.1% | -15.1% |
| EPS | 0.06 | -0.13 | -0.2 | -0.089 |
| % Growth | 146.2% | 35% | -124.2% | – |
| EPS Diluted | 0.06 | -0.13 | -0.2 | -0.089 |
| Weighted Avg Shares Out | 128 | 127 | 126 | 121 |
| Weighted Avg Shares Out Dil | 133 | 127 | 126 | 121 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $3 | $3 | $3 | $6 |
| Depreciation & Amortization | $1 | $1 | $3 | $0 |
| EBITDA | $11 | -$12 | -$19 | -$4 |
| % Margin | 11.2% | -14.7% | -28.3% | -6.2% |